Joint Formulary & PAD

Estradiol - Transgender Health - Children and Young People

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Amber
Formulations :
  • Patches
  • Tablets
Associated Icons :
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Estradiol
Indication :
Transgender Health - Children and Young People
Group Name :
Keywords :
gender reassignment, gender re-assignment, gender identity clinics, GICs, gender incongruence, sex change, transgender, hormonal therapy, feminisation, transsexuals, hormonal treatment, oestrogens, feminising hormones, oestradiol, gender dysphoria
Brand Names Include :
Elleste Solo MX, Estraderm MX, Estradot, Evorel, FemSeven, Progynova TS, Bedol, Climival, Zumenon
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
3

Other Indications

Below are listed other indications that Estradiol is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Transgender Health - Children and Young People.

Committee Recommendations (2)

With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for gender affirming hormones in children and young people.  This applies to recommendations from both NHS and private providers subject to appropriate shared care protocols being in place.

The following guidance has also been updated:

  • Primary care prescribing guidance, for people who access Gender Identity Services.
  • NHSE guidance on prescribing and dispensing restrictions for puberty blockers and gender affirming hormones

In December 2023, a guide to support primary care prescribing for people who access gender identity services was agreed by the APC. 

The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.